longer survival of HBV-ACLF. Additionally, ROC analysis showed that miR125b-5p(AUC=0.814) had higher performance for survival prediction of HBV-ACLF as compared to miR-122 (AUC=0.804), PTA(AUC=0.762) MELD score(AUC=0.799) and TBil(AUC=0.670) alone; and predictive effectiveness of miR125b-5p was greatly increased by the combination of miR122(AUC=0.898).

Conclusions The increasing of serum miR-125b-5p is associated severity of liver damage, and high serum miR-125b-5p may serve as a novel predictor of poor outcome of HBV-ACLF.

IDDF2018-ABS-0106 **TENOFOVIR ALAFENAMIDE (TAF) COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH CHRONIC HBV: WEEK 96 EFFICACY AND SAFETY RESULTS IN CHINESE PATIENTS ENROLLED IN 2 GLOBAL PHASE 3 STUDIES**

¹Henry Lik-Yuen Chan*, ²Wai Kay Seto, ³Scott Fung, ⁴Jinlin Hou, ⁵Calvin Pan, ⁶Wan-Long Chuang, ⁷Ting-Tsung Chang, ⁸Aric-Josun Hui, ⁹Chi-Yi Chen, ¹⁰Tak Yin Owen Tsang, ¹¹Jenny Yang, ¹²John Flaherty, ¹³Anuj Gaggar, ¹⁴Shuyuan Mo, ¹⁵Jia-Horng Kao. ¹Department of Medicine and Therapeutics, Institute of Digestive Disease and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong; ²Queen Mary Hospital, Hong Kong; ³Toronto General Hospital, Toronto, ON, Canada; ⁴Nanfeng Hospital, Guangzhou, China; ⁵New Discovery LLC, Flushing, NY, United States; ⁶Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; ⁷National Cheng Kung University Hospital, Tainan, Taiwan; ⁸Alice Ho Miu Ling Nethersole Hospital, Hong Kong; ⁹Chiayi Christian Hospital, Chiayi, Taiwan; ¹⁰Princess Margaret Hospital, Hong Kong; ¹¹Gilead Sciences, Foster City, CA, United States; ¹²National Taiwan University Hospital, Taipei, Taiwan

10.1136/gutjnl-2018-IDDFbestabstracts.19

Background TAF, a novel prodrug of tenofovir, has demonstrated efficacy noninferior to that of TDF at Week 48 in patients with chronic HBV (CHB) with significantly reduced bone and renal effects. Here we evaluated the efficacy and safety of TAF vs TDF in the subset of patients of Chinese ethnicity enrolled in two overseas studies.

Methods In 2 Phase 3 studies, HBeAg-negative (Study 108) and HBeAg-positive (Study 110) CHB patients were randomised 2:1 to TAF 25 mg QD or TDF 300 mg QD and treated for 96 weeks. In this analysis, the efficacy (HBV DNA).

Results Of 1298 patients randomised and treated, 471 (36%) were of Chinese ethnicity; 156 (TAF 97; TDF 59) and 315 (TAF 207; TDF 108) patients were HBeAg-negative and HBeAg-positive, respectively. For the TAF and TDF groups within each study, baseline characteristics of the study populations were generally similar. Key efficacy results at Weeks 48 and 96 are presented in the Table (table 1). In both HBeAg-negative and HBeAg-positive patients of Chinese ethnicity, the antiviral efficacy of TAF was similar to that of TDF and results were comparable to those in the overall overseas population. Numerically higher percentages of patients treated with TAF achieved normalisation of serum ALT values and anti-HBe seroconversion at Weeks 48 and 96. The safety of TAF and TDF, including changes in renal and bone parameters, were similar to results previously reported in the overall overseas population.

Conclusions In CHB patients of Chinese ethnicity, TAF 25 mg showed similar antiviral efficacy to TDF 300 mg, with less change in bone and renal parameters. Results in this subgroup were comparable to those in the overall population.

Abstract IDDF2018-ABS-0106 Table 1 Efficacy Results at Week 48 and 96

n/N (%)	HBeAg-negative Patients (Study 108)		HBeAg-positive Patients (Study 110)	
	TAF (n= 97)	TDF (n= 59)	TAF (n= 207)	TDF (n= 108)
Week 48				
HBV DNA<29 IU/mL	90 (93%)	55 (93%)	143 (69%)	76 (70%)
ALT normalisation (AASLD criteria) ^a	46/94 (49%)	18/59 (31%)	100/207 (48%)	39/108 (36%)
HBeAg loss	NA ^b	NA	28/204 (14%)	11/103 (11%)
HBeAg seroconversion	NA	NA	23/204 (11%)	8/103 (8%)
Week 96				
HBV DNA<29 IU/mL	88 (91%)	57 (97%)	161 (78%)	86 (80%)
ALT normalisation (AASLD criteria) ^a	46/94 (49%)	24/59 (41%)	119/207 (57%)	46/108 (43%)
HBeAg loss	NA ^b	NA	55/204 (27%)	17/103 (17%)
HBeAg seroconversion	NA	NA	47/204 (23%)	13/103 (13%)

All results are reported as missing=failure; ^aUpper limit of normal (ULN) 30 U/L males, 19 U/L females; ^bNA, not applicable.

IDDF2018-ABS-0113 **THE SAFETY AND TOLERABILITY OF SOF/VEL/VOX FOR 8 OR 12 WEEKS IN >1,000 PATIENTS TREATED IN THE POLARIS-1, POLARIS-2, POLARIS-3, AND POLARIS-4 STUDIES: AN INTEGRATED ANALYSIS**

¹Michael P Manns*, ²Edward Gane, ³Bernard E Willems, ⁴Stuart K Roberts, ⁵Steven Flamm, ⁶Marc Bourliere, ⁷Tarik Asselah, ⁸Laurent Alric, ⁹Robert H Hyland, ¹⁰Luisa M Stamm, ¹¹KC Huang, ¹²Diana M Brainard, ¹³Christina SM Yip, Hai Cheng Huang, ¹⁴Mandana Khalili, ¹⁵Graham R Foster, ¹⁶Stuart C Gordon, ¹⁷Reddy K Rajender, ¹⁸Stefan Zeuzem, ¹⁹Ira M Jacobson, ²⁰Curtis L Cooper, ²¹Alex J Thompson, ²²Kris Kowdley, ²³Eric Lawitz. ¹Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; ²Auckland Clinical Studies, Auckland, New Zealand; ³Centre Hospitalier de l'Université de Montréal, Montréal, Canada; ⁴Alfred Hospital, Melbourne, Australia; ⁵Northwestern University, Chicago, USA; ⁶Hospital Saint Joseph, Marseille, France; ⁷Service d'Hépatologie, Hôpital Beaujon, Université Paris Diderot, Clichy, France; ⁸Internal Medicine-Digestive Department, CHU Purpan, URM 152, Toulouse 3 University, Toulouse, France; ⁹Gilead Sciences, Inc., Foster City, CA, USA; ¹⁰University of California San Francisco, San Francisco, USA; ¹¹Royal London Hospital, London, UK; ¹²Henry Ford Health System, Detroit, USA; ¹³University of Pennsylvania, Philadelphia, USA; ¹⁴Johann Wolfgang Goethe University Medical Center, Frankfurt, Germany; ¹⁵Department of Medicine, Mount Sinai Beth Israel, New York, USA; ¹⁶Ottawa Hospital Research Institute, Ottawa, Canada; ¹⁷Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Australia; ¹⁸Swedish Medical Center, Seattle, USA; ¹⁹Texas Liver Institute, University of Texas Health Science Center, San Antonio, USA

10.1136/gutjnl-2018-IDDFbestabstracts.20

Background The once-daily fixed-dose combination tablet of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) was evaluated for the treatment of genotype 1–6 HCV infection in four phase 3 studies in patients with and without compensated cirrhosis. This analysis describes the safety of SOF/VEL/VOX across 4 Phase 3 studies.

Methods Treatment-emergent adverse events (AEs) and laboratory abnormalities were assessed in patients who received SOF/VEL/VOX or placebo for 12 weeks (POLARIS-1), SOF/VEL/VOX or SOF/VEL for 12 weeks (POLARIS-4), or SOF/